Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Zydelig
Pharma
FDA halts single-arm nods for PI3K blood cancer meds
Before the adcomm, the FDA has already dissuaded Incyte from filing its PI3K inhibitor parsaclisib in certain lymphomas based on single-arm data.
Angus Liu
Apr 20, 2022 9:57am
FDA probes TG Therapeutics' Ukoniq for potential death risks
Feb 7, 2022 9:53am
Gilead pulls 2 accelerated approvals in lymphoma
Jan 24, 2022 11:29am
Bayer's Aliqopa leaps ahead of Gilead's Zydelig in lymphoma
Apr 10, 2021 8:30am
Can Epizyme's Tazverik launch top Gilead's Zydelig?
Feb 25, 2020 11:17am
Verastem wins FDA nod for AbbVie-ditched cancer drug Copiktra
Sep 25, 2018 11:41am
